CYTK Overview
Upcoming Projects (CYTK)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (CYTK)
-
A Second View: Exploring the Breakthroughs of Aficamten in Obstructive Hypertrophic Cardiomyopathy: Insights from the SEQUOIA-HCM Phase 3 Clinical Trial
Ticker: CYTK
Executed On: Feb 12, 2024 at 01:00 PM EST -
Exploring the Breakthroughs of Aficamten in Obstructive Hypertrophic Cardiomyopathy: Insights from the SEQUOIA-HCM Phase 3 Clinical Trial
Ticker: CYTK
Executed On: Jan 23, 2024 at 03:00 PM EST -
Discussing aficamten and its potential in obstructive hypertrophic cardiomyopathy (oHCM) in the phase 3 SEQOUIA-HCM trial
Ticker: CYTK
Executed On: Nov 01, 2023 at 01:00 PM EDT -
Examining the data presented on aficamten in non-obstructive hypertrophic cardiomyopathy by Cytokinetics Biopharma
Ticker: CYTK
Executed On: Apr 17, 2023 at 04:30 PM EDT
Expired Projects (CYTK)
-
Discussing Cytokinetics’ Omecamtiv Mecarbil in treating Heart Failure with Reduced Ejection Fraction, in light of February 28 PDUFA
Ticker: CYTK
Execute By: Mar 31, 2023
Upcoming & Overdue Catalysts (CYTK)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (CYTK)
-
Results of Phase 3 VITALITY-ALS Trial of Lead Drug Candidate Tirasemptiv Projected Q3 of 2017
Ticker: CYTK
Occurred on: Nov 21, 2017 -
Phase 2 Study Results of CK-2127107 on Patients with Spinal Muscular Atrophy Expected mid-2017
Tickers: CYTK, TSE:4503
Occurred on: Jul 05, 2017 -
Cytokinetics Announces Start of Phase 1b Clinical Trial of CK-2127107 in Elderly Subjects With Limited Mobility
Tickers: CYTK, ALPMY
Occurred on: Jun 29, 2017 -
Development of Omecamtiv Mecarbil Questionable to Continue to Phase 3 - Decision Expected This Year
Tickers: CYTK, AMGN
Occurred on: Sep 01, 2016 -
Cytokinetics expect to complete target enrollment of 600 patients in VITALITY-ALS in the first half of 2016
Ticker: CYTK
Occurred on: Aug 17, 2016 -
Additional Phase 2 Study of CK-2127107 in Patients with COPD Set to Initiate 1H of 2016
Tickers: CYTK, TSE:4503
Occurred on: Jun 30, 2016
Strategic Initiatives (CYTK)
-
Origent Data Sciences and Cytokinetics Announce Research Collaboration on Predictive Analytics Model in ALS
Tickers: ORIGENT, CYTK
Announcement Date: Mar 31, 2016
